Singapore · Investor

Bio*One Capital

Last cheque observed Oct 2013. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietCorporate VC

Series DSeries BSeries C

Cheques on record
0%of best year0cheques in 12 months, 20 on record
Since the last cheque4766days00hrs00min00sec
Median round$21MRounds led0 of 20Exits5 from the portfolioMostly inUnited States, 80%
Pitch Bio*One Capital

Bio*One Capital highlights

  1. 01

    20 rounds on record

  2. 02

    Mostly Series D and Series B: 42% of its rounds

  3. 03

    5 exits from the portfolio

What they do

Type
Corporate VC (from a list, unverified)
Cheque size
Not stated
Based in
Singapore
Cold pitches
Not stated

The record

Every round we can evidence, newest first20 appearances

  1. 2013

    1 round

  2. Oct
    Amaranth MedicalSeries B · US · amaranthmedical.com$20MWith 3 others
  3. 2010

    4 rounds

  4. Oct
    MerLion PharmaceuticalsSeries C · SG · onbiovc.com$7.0MWith 2 others
  5. Oct
    TriReme MedicalSeries D · US · prnewswire.com$17MWith 2 others
  6. Jul
    Artisan PharmaSeries C · US · masshightech.com$3.0MWith 4 others
  7. Mar
    Artisan PharmaSeries B · US · artisanpharma.net$22MWith 3 others
  8. 2009

    3 rounds

  9. Dec
    FORMA TherapeuticsSeries B · US · masshightech.com$3.0MWith 3 others
  10. Dec
    FORMA TherapeuticsSeries B · US · altassets.com$26MWith 3 others
  11. Oct
    InviragenSeries A · US · inviragen.com$15MWith 3 others
  12. 2008

    1 round

  13. Oct
    S*BioVenture · SG$26MWith 5 others
  14. 2007

    3 rounds

  15. Dec
    Pelikan TechnologiesSeries F · US · venturebeat.com$69MWith 2 others
  16. Jan
    FluidigmSeries E · US · deals.venturebeat.com$17MWith 9 others
  17. Jan
    FluidigmSeries E · US$37MWith 7 others
  18. 2006

    4 rounds

  19. Sept
    RenaMed BiologicsVenture · US · venturecapitalreporter.com$40MWith 8 others
  20. Sept
    Artisan PharmaSeries A · US · artisanpharma.net$39MWith 4 others
  21. Aug
    CodexisSeries D · US · codexis.com$37MWith 4 others
  22. Jul
    Takeda CambridgeSeries D · GB$13MWith 2 others
  23. 2005

    1 round

  24. Jan
    Takeda CambridgeVenture · GB$9.4MWith 2 others
  25. 2004

    2 rounds

  26. May
    MicrobiaSeries D · US$40MWith 3 others
  27. Feb
    Kadmus PharmaceuticalsSeries A · US$15MWith 6 others
  28. 2003

    1 round

  29. Jan
    Raven BiotechnologiesSeries C · US$40MWith 8 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed5 in all

InviragenBought by Takeda PharmaceuticalUndisclosedMay 2013
Artisan PharmaBought by Asahi Kasei PharmaUndisclosedNov 2011
MicrobiaBought by DSMUndisclosedSept 2010
CodexisListedUndisclosedApr 2010
Raven BiotechnologiesBought by MacroGenicsUndisclosedJul 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Bio*One Capital. A count of rooms they were both in, not a relationship either has claimed.

Jafco VenturesGrowth equity3rounds togetherLilly VenturesCorporate VC3rounds togetherNGN CapitalVC firm3rounds togetherAlloy VenturesVC firm2rounds togetherAravis VenturesPrivate equity2rounds togetherAvlar BioVenturesInvestment firm2rounds togetherCMEA VenturesVC firm2rounds togetherCharter Life SciencesVC firm2rounds togetherEuclidSR PartnersGrowth equity2rounds togetherInterWest PartnersVC firm2rounds togetherMerlin BiosciencesGrowth equity2rounds togetherNew Leaf Venture PartnersVC firm2rounds together

Quick answers about Bio*One Capital

What does Bio*One Capital invest in?

Bio*One Capital invests most often at Series D and Series B (42% of the rounds on record).

How active is Bio*One Capital?

20 investments on record, 0 of them in the last 12 months. The most recent was in Oct 2013.

How big are Bio*One Capital's cheques?

The median round it joins is $21M.

Does Bio*One Capital lead rounds?

Rarely, if at all: none of its 20 investments on record names it as the lead.

Where does Bio*One Capital invest?

Most of the companies it backs are in the United States (80%), Singapore (10%) and the United Kingdom (10%).

Is Bio*One Capital investing now?

No investments in the last 12 months; the latest was in Oct 2013.

Who does Bio*One Capital invest alongside?

Most often Jafco Ventures (3 rounds together), Lilly Ventures (3 rounds together) and NGN Capital (3 rounds together).

What kind of investor is Bio*One Capital?

Bio*One Capital is a corporate VC based in Singapore.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it